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fusion of the inner and outer cell membranes, forming a specific
transmembrane tunnel structure through which all the cytoplasmic
content is expelled, thus leaving a bacterial envelope called a BG
devoid of nucleic acids, ribosomes and other intracellular constitu-
ents. The inner membrane (IM) and outer membrane (OM) structures
of BGs remain intact during the lysis process. Electron microscopy
studies and enzymatic studies clearly showed a sealed periplasmic
space at the border of the lysis tunnel. The efficiency of the E-medi-
ated lysis process, and quantification of generated BGs and non lysed
viable bacteria are determined by flow cytometry assays using a spe-
cific dye that is sensitive to the changes of discriminatory power of
membrane potential and stains only cells that have lost membrane
potential (BGs or dead bacteria).
Bacterial ghosts as advanced drug delivery systems: Many dis-
eases including cancers require the systemic administration of highly
aggressive drugs to already immunocompromised patients. Deleteri-
ous and often severe side effects result from a lack of cellular and tis-
sue selectivity. Another major issue is the poor solubility of some
drugs used in cancer treatment. Considering these limitations, the
development of a safer and more efficient drug delivery system
(DDS) is the priority for future advanced cancer treatments. Recently,
bacterial ghosts made from the colonic commensal Mannheimia hae-
molytica were used for in vitro delivery of doxorubicin (DOX) to
human colorectal adenocarcinoma (Caco-2) cells.
Adherence studies showed that the M. haemolytica ghosts targeted
the Caco-2 cells and released the loaded DOX within the cells. Cyto-
toxicity assays showed a two folds enhancement in cytotoxic and
anti-proliferative activity in cells incubated with DOX-loaded ghosts
as compared with cells for which DOX was directly added to the cul-
ture media. This phenomenon might be caused by degradation of
DOX-loaded BGs within the endo-lysosome of target cells allowing
DOX to bypass the multi-drug resistance (MDR) efflux pumps and
resulting in enhanced accumulation of DOX in the cytoplasm and
then in the nuclear area of target cells. Current work with bacterial
ghosts lies in the investigation of the carrier capacity of the cytoplas-
mic lumen. This intracellular space of BGs can be filled either with
water-soluble substances or emulsions such that the drug(s) of interest
can be coupled to streptavidin anchored on the inside of the cytoplas-
mic membrane. Moreover, bacterial ghosts can be filled and sealed
for the delivery of fluid, non-anchored substances. In a recent study,
E. coli ghosts were filled with the reporter substance calcein and were
sealed by fusion with membrane vesicles to maintain inner membrane
integrity. Adherence and uptake studies showed that murine macro-
phages and human Caco-2 cells took up the bacterial ghosts, and cal-
cein was released within the cells.
Bacterial ghosts as immunologically active particles: Because
of the unique structure of the BG’s envelope with preserved patho-
gen-associated molecular patterns (PAMPs), BGs can be used in bio-
medicine alone as an adjuvant or as a delivery vehicle for drugs or
genes. The inner space of BG’s empty envelope can be loaded with
a combination of peptides, drugs or foreign DNA which gives us an
opportunity to design new types of polyvalent vaccines. BGs have
excellent DNA loading capacity varying from 4000 to 6000 plasmid
copies per BG depending on the concentrations of DNA solution
used. BGs loaded with plasmid DNA are efficiently internalized
and phagocytozed by both professional APCs and tumor cells.
Cross-presentation of Ag delivered to dendritic cells (DCs) by BGs
can activate both CD4+ and CD8+ T cells and stimulate the immune
system to enhance the immune response against Ag expressed by tar-
get cells. Inner and outer membrane structures of BGs includinglipopolysaccharide (LPS) and other PAMPs remain intact after pro-
tein E-mediated lysis of Gram-negative bacteria. Thus, beside pos-
sessing a high loading capacity; BGs carry highly effective
molecules for the stimulation of cross presentation by DCs on their
surface, specially, tumor-associated antigens (TAAs). BGs with their
intact envelope structures are not only immune stimulatory to profes-
sional phagocytes but are also capable of providing stimulatory sig-
nals to tumor cells. It is known that melanoma cells have the
capacity to behave as non-professional APCs and can phagocyte
both apoptotic and live cells, and it was recently shown that mela-
noma cells actively respond to exposure to BGs by increasing their
rate of phagocytosis. Using BGs for gene delivery to the immuno-
competent cells, in particular DCs as well as tumor cells, could ini-
tiate or restore the immune response against the delivered TAAs as
well as induce and increase the expression of target genes by APCs
and tumor cells.
Conclusions: These observations indicate high capacity of BGs to
target various histological types of cancers. BGs are very useful non-
living carriers, as they can carry foreign antigens, nucleic acids and
drugs in one or more cellular locations simultaneously. Optimization
and improvement of the selected prospective model type of BGs
would help to progress the development of microbial-mediated dis-
ease treatment and drug delivery systems and their application in
future clinical trials.
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Extended Abstract
Introduction: Cancer is one of the most major and prevalent
health problems around the world that shows high mortality rate.
There have been many researches on the advantages of camel milk
(CM) in cancers. Camel milk is very rich in nutrition and it is used
in the treatment of different diseases. Traditionally, the use of camel
milk in the treatment and prevention of various diseases existed in
Iran, India and Arabic countries. Recent research findings prove the
effectiveness of camel milk in the treatment of diabetes, milk and
food allergies, autism, liver toxicity, hepatitis and cancers. Cell cul-
ture and animal studies introduce camel milk as a new option in can-
cer treatment.
Materials and method: Electronic databases including PubMed,
Scopus, and Cochrane library were searched to access articles giv-
ing any in vitro, in vivo, and human evidences on the efficacy of
CM in the treatment of cancer. Out of 80 records were found in
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analysis.
Results: Based on a few studies, CM shows antioxidant, anti-
cytotoxic, anticlastogenesis and DNA damage inhibitory activities.
Abdulqader A.et al(2013) tested that camel milk inhibited inflam-
matory angiogenesis via downregulation of proangiogenic and
proinﬂammatory cytokines in mice. Hala M.F et al (2014)
reported that camel milk inhibited murine hepatic carcinogenesis,
initiated by diethyl nitrosamine and promoted by phenobarbitone
in male rats. CM also inhibits the progression of hepatocellular
carcinoma. M. Quita Salwa et al (2010) demonstrated antigeno-
toxic and anticytotoxic effects of camel milk in mice treated
with cisplatin.
Hesham M. Korashy, et al (2012) reported that camel milk trig-
gered apoptotic signaling pathways of human hepatoma HepG2
and breast cancer MCF7 cell lines through transcriptional
mechanisms.
Discussion: The main components of camel milk giving insight
into the its potential therapeutic benefits underlying the anticancer
actions are as follows:
1- The vitamin C content in camel’s milk is about three times
higher than that in cows’ milk. Ascorbic acid protects DNA against
oxidative damages.
2. The Selenium content of CM is comparable to those of other
types of milk. Selenium is a constituent of various oxidation defen-
sive selenioproteins and a cofactor of glutathione peroxidase in the
elimination of peroxide radicals.
3. The zinc content of camel’s milk was higher than that of human
milk. Zinc is an element required for DNA and RNA synthesis and
may be a cofactor in the activity of superoxide dismutase. The protec-
tive effect of zinc on cadmium Genotoxicity (the number of micro-
nucleated cells decreased) was observed.
4. The antimutagenic potential of casein was investigated using
several mutagens.
5- Camel milk lactoferrin reduces the proliferation of colorectal
cancer cells and exerts antioxidant and DNA damage inhibitory
activities.
6. There are high levels of linoleic acids (CLA) among the poly-
unsaturated fatty acids in camel milk. CLA compounds could serve as
useful food antioxidants and provide additional value because of their
potential bioactivity in disease prevention. The results obtained by
Liew et al. (1995) supported a mechanism involving the inhibition
of carcinogen activation by CLA, as opposed to direct interaction
with procarcinogen, scavenging of electrophiles or selective induction
of phase I detoxification pathways.
Conclusion: The results are indicative of the remarkable prop-
erties of camel milk in the control and treatment of cancer. The
main factor responsible for anticancer properties of camel milk is
not yet known. It is expected that the antioxidant properties of
camel milk plays an important role in its anticancer activities. In
order to prove the properties listed, clinical studies will be very
helpful.
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Extended Abstract
Introduction: Since microRNAs (miRNAs) discovery, the knowl-
edge on miRNAs and cancer has been increasing exponentially (Fig-
ure 1). The first miRNA was discovered in 1993 by Victor Ambros
and colleagues. By the year 2000, the Ambros and Ruvkun laborato-
ries had discovered the two founding members of a family of small
non-coding RNAs, now called miRNAs.
The detection of mature miRNA transcripts (21~22 nt transcripts)
originated from larger precursor transcript. Two processes are neces-
sary for generation of mature miRNAs: (i) pre-miRNAs from pri-
miRNAs in the nucleus by Drosha and (ii) processing of pre-miRNAs
into mature miRNAs in the cytoplasm by Dicer. The biological role
and in vivo functions of most mammalian miRNAs are very different.
In invertebrates, miRNAs regulate developmental timing, neuronal
differentiation, cell proliferation, growth control, and programmed
cell death. In mammals, miRNAs have been found to play a role in
embryogenesis and stem cell maintenance, hematopoietic cell differ-
entiation, and brain development. Till now, microRNAs expression
has been found to be deregulated in a wide range of human diseases
including cancer.
MiRNAs in cancer: The first report for miRNAs role in cancer,
only two years after the discovery of the first human miRNA, by
George Calin and colleagues was published. Up to day a lot of
papers show miRNAs play a role in tumor invasion and metastasis.
Many aspects of miRNAs roles such as MicroRNA networks in can-
cer, MicroRNAs as predictors of prognosis, MicroRNAs for classi-
fication of disease , MicroRNA polymorphisms predisposing
cancer, MicroRNAs as non-invasive biomarkers and MicroRNAs
as predictors of drug efficacy, was studied. One of the most impor-
tant challenges to overcome cancer is early identification by bio-
markers. A lot of studies highlight the potential of miRNAs as
biomarkers for cancer, Furthermore the mutational status of miRNA
binding sites in their protein coding targets can also be regarded as a
diagnostic tool. Also, exist to strategy for MiRNAs as therapeutic
agents. MiRNA inhibition was the first approach used to explore
the potential of miRNAs in cancer therapy. The second strategy of
miRNA therapeutics is to use miRNAs as a therapeutic agent as
a replacement strategy.
Conclusions: Over recent years, miRNAs have emerged as
major players in the complex networks of gene regulation and
have been implicated in various aspects of human disease. These
small RNAs have already significantly improved our understanding
of carcinogenesis. microRNAs represent critical regulators
of tumor cell differentiation, proliferation, cell cycle progression,
invasion and metastasis. Based on microRNA arrays various
